Лечение рецидивов одной из форм лимфом у кошек
М
МарГера
Терапия циклофосфамидом рецидивирующей после лечения хлорамбуцилом низкодифференцированной алиментарной лимфомы у кошек
Результаты
В исследование было включено 20 кошек.
У 18 кошек получен полный клинический ответ с медианой - 239 дней.
Медиана выживаемости без прогрессии - 215 дней.
Медиана общей выживаемости - 1065 дней.
Заключение
Лечение Циклофосфамидом, по-видимому, является безопасным и эффективным средством первой помощи кошкам с рецидивом данной формы лимфомы.
https://pubmed.ncbi.nlm.nih.gov/33645321/
Cyclophosphamide rescue therapy for relapsed low-grade alimentary lymphoma after chlorambucil treatment in cats
Changseok Kim, Raelene M Wouda, Juan Borrego, Esther Chon
Journal of Feline Medicine and Surgery 23 (10), 976-986, 2021
Objectives
The aims of this study were to evaluate the response, outcome and prognostic factors in cats with clinically presumed relapsed low-grade alimentary lymphoma (LGAL) receiving cyclophosphamide as a first-line rescue therapy after failing chlorambucil treatment.
Methods
The medical records of 20 cats (from three institutions, between 2002 and 2017) treated with cyclophosphamide for relapsed LGAL after initial treatment with chlorambucil were retrospectively reviewed. Progression-free survival (PFS), overall survival time (OST) and the association of select variables with measures of outcome were assessed. Adverse events (AEs) were also described.
Results
Eighteen cats (90%) achieved a complete clinical response (CR) for a median duration of 239 days. The median PFS was 215 days. The median OST was 1065 days. The only clinical factor associated with a longer PFS was achievement of a CR with cyclophosphamide treatment. Cyclophosphamide was associated with few and reversible constitutional, gastrointestinal and hematologic AEs.
Conclusions and relevance
Cyclophosphamide appears to be a safe and effective first-rescue therapeutic option for cats with relapsed LGAL.
[Сообщение изменено пользователем 07.04.2023 13:02]
Результаты
В исследование было включено 20 кошек.
У 18 кошек получен полный клинический ответ с медианой - 239 дней.
Медиана выживаемости без прогрессии - 215 дней.
Медиана общей выживаемости - 1065 дней.
Заключение
Лечение Циклофосфамидом, по-видимому, является безопасным и эффективным средством первой помощи кошкам с рецидивом данной формы лимфомы.
https://pubmed.ncbi.nlm.nih.gov/33645321/
Cyclophosphamide rescue therapy for relapsed low-grade alimentary lymphoma after chlorambucil treatment in cats
Changseok Kim, Raelene M Wouda, Juan Borrego, Esther Chon
Journal of Feline Medicine and Surgery 23 (10), 976-986, 2021
Objectives
The aims of this study were to evaluate the response, outcome and prognostic factors in cats with clinically presumed relapsed low-grade alimentary lymphoma (LGAL) receiving cyclophosphamide as a first-line rescue therapy after failing chlorambucil treatment.
Methods
The medical records of 20 cats (from three institutions, between 2002 and 2017) treated with cyclophosphamide for relapsed LGAL after initial treatment with chlorambucil were retrospectively reviewed. Progression-free survival (PFS), overall survival time (OST) and the association of select variables with measures of outcome were assessed. Adverse events (AEs) were also described.
Results
Eighteen cats (90%) achieved a complete clinical response (CR) for a median duration of 239 days. The median PFS was 215 days. The median OST was 1065 days. The only clinical factor associated with a longer PFS was achievement of a CR with cyclophosphamide treatment. Cyclophosphamide was associated with few and reversible constitutional, gastrointestinal and hematologic AEs.
Conclusions and relevance
Cyclophosphamide appears to be a safe and effective first-rescue therapeutic option for cats with relapsed LGAL.
[Сообщение изменено пользователем 07.04.2023 13:02]
Авторизуйтесь, чтобы принять участие в дискуссии.